Protagenic Therapeutics Reports Multiple Material Events
Ticker: PTIXW · Form: 8-K · Filed: May 19, 2025 · CIK: 1022899
| Field | Detail |
|---|---|
| Company | Protagenic Therapeutics, Inc.\New (PTIXW) |
| Form Type | 8-K |
| Filed Date | May 19, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-event, acquisition, equity-sale, corporate-action
Related Tickers: PTIX
TL;DR
PTIX filed an 8-K detailing acquisitions, equity sales, and officer changes. Big moves happening.
AI Summary
Protagenic Therapeutics, Inc. filed an 8-K on May 19, 2025, reporting several material events. These include entering into a material definitive agreement, completion of an acquisition or disposition of assets, unregistered sales of equity securities, and material modifications to security holder rights. The filing also details changes in directors or officers and compensatory arrangements, amendments to articles of incorporation or bylaws, and other events including Regulation FD disclosures and financial statements.
Why It Matters
This 8-K filing indicates significant corporate actions by Protagenic Therapeutics, potentially impacting its business structure, financial standing, and shareholder rights.
Risk Assessment
Risk Level: medium — The filing covers a broad range of material events including acquisitions and equity sales, which can introduce significant business and financial risks.
Key Players & Entities
- Protagenic Therapeutics, Inc. (company) — Filer of the 8-K
- Atrinsic, Inc. (company) — Former company name
- NEW MOTION, INC. (company) — Former company name
- MPLC, Inc. (company) — Former company name
- 20250519 (date) — Filing date
- 20250515 (date) — Period of report
FAQ
What specific material definitive agreement did Protagenic Therapeutics enter into?
The filing does not specify the details of the material definitive agreement, only that one was entered into.
What acquisition or disposition of assets was completed by Protagenic Therapeutics?
The filing indicates the completion of an acquisition or disposition of assets but does not provide specific details about the transaction.
What were the details of the unregistered sales of equity securities?
The filing mentions unregistered sales of equity securities but does not provide specific details such as the number of shares or the price.
Were there any changes in the board of directors or executive officers?
Yes, the filing indicates potential changes in directors or certain officers, as well as the appointment of officers and compensatory arrangements.
What amendments were made to Protagenic Therapeutics' articles of incorporation or bylaws?
The filing lists 'Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year' as an item, but the specific amendments are not detailed in the provided text.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 19, 2025 regarding Protagenic Therapeutics, Inc.\new (PTIXW).